Financial Performance Highlights

Q2 FY27 Performance (Quarter Ended September 30, 2026):

  • Total Income: ₹267.64 crores, representing 84.21% YoY growth (vs. ₹145.29 crores in Q2 FY26)
  • EBITDA: ₹42.6 crores, representing 90.74% YoY growth
  • EBITDA Margin: 15.92%, expanded by 55 basis points
  • Net Profit: ₹18.83 crores, representing 93.44% YoY growth
  • Net Profit Margin: 7.03%, expanded by 34 basis points

H1 FY27 Performance (Half Year Ended September 30, 2026):

  • Total Income: ₹495.88 crores, representing 87.02% YoY growth
  • EBITDA: ₹75.38 crores, representing 91.67% YoY growth
  • EBITDA Margin: 15.20%, expanded by 37 basis points
  • Net Profit: ₹31.99 crores, representing 93.92% YoY growth
  • Net Profit Margin: 6.45%

Guidance and Outlook

Management confirmed the company will exceed its previously stated FY27 revenue target of ₹800 crores, citing a history of consistently overachieving guidance for the past 10 years. The H1 performance corroborates this expectation, with management anticipating similar traction in the coming two quarters.

Business Segment Performance

The company operates across multiple verticals:

  • Vintage Business (Legacy Formulations): Growing at 15-25% YoY on a higher base
  • New Age Businesses: Growing at 65-80% YoY on smaller bases
  • Pet Care: ~70-80% growth
  • Mobility: ~65-70% growth
  • Mass Market Cosmetics: ~65-70% growth
  • Dermaceutics: Strong growth
  • Nutraceuticals: Strong growth

Management emphasized that the current growth represents only the "first floor of the building," with the main inflection point expected in the next 18-24 months as ecosystems mature and dots connect.

Strategic Initiatives and Updates

Product Portfolio: The company now has approximately 2,400 products in its portfolio, allowing for selective focus on higher-yielding products.

Vetcare Investment: The company holds a 26% stake in Vetcare, described as a pioneer in pet retail with four decades of experience. The investment is focused on profitable growth (no burn model) with integration planned between Vetcare's retail expertise and Fredun's doctor reach.

New Product Launches:

  • CAT (hormonal products) launch planned for January 2027
  • Daulcél anti-aging line in launch phase
  • Hormonal products to be sold nationwide through innovative channels

Wagr Platform: Described as more than an e-commerce platform, it's being developed as a comprehensive pet ecosystem with a 45-person team working extensively.

Management Commentary

Growth Strategy: The company is transforming from a typical pharma manufacturing company to a consumer product company with higher intrinsic profitability. Management emphasized creating niches within sectors and focusing on higher margin profiles than competitors.

Competitive Advantages: Management highlighted significant barriers to replication including:

  • Time-intensive license acquisition (15-16 years for some licenses)
  • Extensive research periods (11 years of research on herbal products)
  • Large datasets in diagnostics enabling accuracy
  • Educational programs building influencer networks
  • First-mover advantages in several segments

Financial Controls: Addressing CARE Ratings deviations, management acknowledged technical reporting issues and confirmed:

  • A professional CFO is being trained and will be announced in coming months
  • Internal audit team appointed
  • Various audit checks implemented
  • Reporting standards and speed improving